New Horizon Health Limited (6606.HK, “NHH” or “Company”), a VMS invested company, has been selected by the Shenzhen Stock Exchange as an eligible stock of Hong Kong Stock Connect for mainland investors with effect from June 7, 2021.

The Company has also been selected as a constituent stock of the following benchmark and thematic indexes by Hang Seng Indexes Company Limited, also with effect from June 7, 2021.

• Hang Seng Composite Index
• Hang Seng Large-Mid Cap (Investable) Index
• Hang Seng Healthcare Index
• Hang Seng Stock Connect Hong Kong Index
• Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index
• Hang Seng SCHK Mainland China Companies Index
• Hang Seng SCHK ex-AH Companies Index
• Hang Seng Hong Kong-Listed Biotech Index

Founded in 2015, NHH is a cancer screening market leader, focusing on the design, development and commercialization of cancer screening tests. The Company’s vision is to prevent and cure cancer by screening and early detection.

VMS led its series C round of financing in 2019 and later participated in series D in 2020. NHH was successfully listed on the Hong Kong Stock Exchange on February 5, 2021 and its share price has risen significantly to close at HKD 79.75/share as of June 7, 2021. The stellar share price performance indicates that the value of NHH is well acknowledged by the market.

We view the inclusion of NHH in the Stock Connect program and various benchmarks as the capital market’s recognition of the Company’s business performance and growth outlook. The inclusion helps broaden the Company’s investor base, enhance trading liquidity and brand awareness.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.